In this special episode of Molecule to Market, recorded at this year’s CDMO Live in Rotterdam, industry leaders come together to assess the evolving state of the contract development and manufacturing sector. Raman is the panel moderator, joined by:
Gil Roth - PBOA
Dr. Jim Li - BioDuro Sundia
Kaan-Fabian Kekec - Simon-Kucher
They unpack cautious optimism in the face of lingering market uncertainties and geopolitical tension, you’ll hear:
How CDMO...
In this special episode of Molecule to Market, recorded at this year’s CDMO Live in Rotterdam, industry leaders come together to assess the evolving state of the contract development and manufacturing sector. Raman is the panel moderator, joined by:
- Gil Roth - PBOA
- Dr. Jim Li - BioDuro Sundia
- Kaan-Fabian Kekec - Simon-Kucher
They unpack cautious optimism in the face of lingering market uncertainties and geopolitical tension, you’ll hear:
- How CDMOs are adapting to early-stage funding strain and evolving pricing models
- The impact of rising interest rates, tariffs, and global trade policy on pharma outsourcing
- Capacity and talent constraints facing CDMOs in new therapeutic modalities
- Why integrated models and scenario planning are key to future-proofing operations
This episode offers timely insight into the challenges and opportunities shaping the next phase of growth for CDMOs worldwide.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.
View more